Clinical Trial Update: The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating N-acetyl-L-cysteine as an adjuvant to opioid therapy for chronic neuropathic pain; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain

Drugs mentioned

• N-acetyl-L-cysteine (N-acetylcysteine)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Neuropathic Pain | Phase 2 | Status: COMPLETED | Results posted: 2018-05-14